Fig. 7

Upregulation of miR-340-5p indicates radioresistance and correlates with a poor response to radiotherapy in OSCC patients. a qRT-PCR analysis of miR-340-5p levels in tissues and plasma exosomes of OSCC patients with and without in-field recurrence within 3 years post radiotherapy. b-c Kaplan-Meier survival analysis of in-field recurrence free survival (b) and overall survival (c) of OSCC patients with different histological and plasma exosomal miR-340-5p levels 3 years post radiotherapy. d Expression of plasma exosomal miR-340-5p in 10 OSCC patients receiving neoadjuvant chemoradiotherapy. e Expression of KLF10 was negatively correlated with the plasma exosomal miR-340-5p levels in 40 OSCC patients. f-g Expression of KLF10 in OSCC tissues (f) and plasma EVs (g) was detected by qRT-PCR in clinical samples of patients with different miR-340-5p levels. h IHC showing the expression of KLF10 in clinical specimens expressing different miR-340-5p levels. i Schematic diagram showing that metformin attenuates hypoxic tumour cell-orchestrated radioresistance cascades